Here, we examined the ability of TTI-101 to treat CRC in the AOM-DSS mouse model of colitis-induced CRC and demonstrated that TTI-101 markedly reduced colon tumors in this model, at least in part, by normalizing the STAT3-driven pro-oncogenic transcriptome in colonic mucosa. The gene discussed is STAT3; the disease is colorectal carcinoma.